HOME >> BIOLOGY >> NEWS
Cost-effectiveness of treating multidrug-resistant tuberculosis

Researchers have made predictions as to how the tuberculosis (TB) epidemic in Peru might progress over the next 30 years, depending on what measures are used to fight it. They considered the five different approaches to treating drug-resistant TB that are open to the Peruvian health authorities.

TB is a growing problem worldwide. Most cases can be treated effectively with a standard treatment (known as 'DOTS', which stands for 'Directly Observed Therapy Short-Course') but an increasing number of cases are resistant to all the various 'first-line' treatment drugs; this is known as multi-drug resistant (MDR) TB. MDR-TB must be treated with 'second-line' drugs. There are several different options; for example, doctors could give second-line drugs whenever a first attempt at treatment has failed, or only use these drugs in cases where tests have confirmed MDR-TB to be the problem. MDR-TB cases could all be given the same standard treatment or, based on tests, each could have 'individualized' treatment.

The researchers used a method called 'modelling'. They performed calculations based on information already available about TB in Peru, where there are 120 new TB infections per 100,000 people every year and 4.5% of existing cases have MDR-TB. They concluded that use of second-line drugs would be cost-effective for Peru and that, despite the extra costs of individualized treatment, this is the best option. The results will be of interest in other developing countries. The researchers say, "In other settings, the attractiveness of strategies using second-line drugs will depend on TB incidence, MDR burden, and the available budget, but simulation results suggest that individualized regimens would be cost-effective in a wide range of situations". They also stress it is important for the standard first-line DOTS treatment to be made widely available.


'"/>

Contact: Andrew Hyde
ahyde@plos.org
44-122-346-3330
Public Library of Science
3-Jul-2006


Page: 1

Related biology news :

1. Cost-effectiveness study of three antimalarial drug combinations in Tanzania
2. Brain blood flow gives clues to treating depression
3. New strategy for treating allergic disorders
4. Developer of new method for treating bone defects wins WPI Entrepreneurship Award
5. UCF nanoparticle offers promise for treating glaucoma
6. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
7. 8 plants from South Africa may hold potential for treating high blood pressure
8. Arctic ice retreating more quickly than computer models project
9. Nanotechnology offers hope for treating spinal cord injuries, diabetes and Parkinsons disease
10. Discovery in plants suggests entirely new approach to treating human cancers
11. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts

Post Your Comments:
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
(Date:7/31/2015)... julho de 2015 A 10 a. ... realizada pela BGI de 22-25 de outubro de 2015, em ... A conferência está celebrando seu 10 o. aniversário este ... tornou uma das reuniões mais influentes do mundo no ... dinâmicos, entusiastas e prazerosos. A ICG-10 ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "DNA ... their offering. This report briefly reviews ... technologies, and their applications. Current large and small ... them. Various applications of sequencing are described including ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... of the winners of the 2015 BeHEARD science challenge, ... that offers rare disease researchers, access to the latest ... use its drug repositioning and pathway analytics capability to ... Wylder Nation Foundation in the study of Niemann-Pick Disease ...
(Date:9/2/2015)... Australian prostate cancer technology company Minomic International Ltd has ... science that uses its patented antibody. The ... cancer diagnostic test known as MiCheck® next year, was ... peer-reviewed Australian Museum Eureka Science Prize for Excellence ... is awarded for ground breaking research that has only ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3
Cached News: